estriol has been researched along with Demyelinating Diseases in 1 studies
hormonin: estrogen replacement; each tablet contains 600 ug micronized 17beta-estradiol, 270 ug estriol and 1.4 mg estrone
chlorapatite : A phosphate mineral with the formula Ca5(PO4)3Cl.
Demyelinating Diseases: Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Estriol treatment prevented decreases in excitatory synaptic transmission and lessened the effect of EAE on PPF." | 1.38 | Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease. ( Avedisian, AA; Dervin, SM; O'Dell, TJ; Voskuhl, RR; Ziehn, MO, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ziehn, MO | 1 |
| Avedisian, AA | 1 |
| Dervin, SM | 1 |
| O'Dell, TJ | 1 |
| Voskuhl, RR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind, Placebo Controlled Trial of Estriol Treatment in Women With Multiple Sclerosis: Effect on Cognition.[NCT01466114] | Phase 2 | 64 participants (Anticipated) | Interventional | 2011-10-31 | Recruiting | ||
| A Combination Trial of Copaxone Plus Estriol in RRMS[NCT00451204] | Phase 2 | 158 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
A confirmed relapse was defined as new neurological symptoms or worsening of pre-existing symptoms, lasting at least 48 hours in a subject who had been neurologically stable or improving in the previous 30 days, accompanied by objective change in the neurological examination (worsening of 0.5 points on the EDSS or worsening by 1.0 or more points on the pyramidal, cerebellar, brainstem or visual functional system scores), not due to fatigue alone and not associated with fever or infection. (NCT00451204)
Timeframe: 12 months
| Intervention | relapses per year (Mean) |
|---|---|
| Estriol Capsules Plus Copaxone Injections | 0.25 |
| Placebo Capsules Plus Copaxone Injections | 0.48 |
A confirmed relapse was defined as new neurological symptoms or worsening of pre-existing symptoms, lasting at least 48 hours in a subject who had been neurologically stable or improving in the previous 30 days, accompanied by objective change in the neurological examination (worsening of 0.5 points on the EDSS or worsening by 1.0 or more points on the pyramidal, cerebellar, brainstem or visual functional system scores), not due to fatigue alone and not associated with fever or infection. (NCT00451204)
Timeframe: 24 months
| Intervention | relapses per year (Mean) |
|---|---|
| Estriol Capsules Plus Copaxone Injections | 0.25 |
| Placebo Capsules Plus Copaxone Injections | 0.37 |
(NCT00451204)
Timeframe: 24 months
| Intervention | probability of relapse at 24 months (Mean) |
|---|---|
| Estriol Capsules Plus Copaxone Injections | 33.3 |
| Placebo Capsules Plus Copaxone Injections | 42.9 |
Met all criteria for relapse except not confirmed to have increase in EDSS by an independent examiner. (NCT00451204)
Timeframe: 12 months
| Intervention | relapses per year (Mean) |
|---|---|
| Estriol Capsules Plus Copaxone Injections | 0.33 |
| Placebo Capsules Plus Copaxone Injections | 0.61 |
Met all criteria for relapse except not confirmed to have increase in EDSS by an independent examiner. (NCT00451204)
Timeframe: 24 months
| Intervention | relapses per year (Mean) |
|---|---|
| Estriol Capsules Plus Copaxone Injections | 0.32 |
| Placebo Capsules Plus Copaxone Injections | 0.46 |
(NCT00451204)
Timeframe: 24 months
| Intervention | probability of relapse event at 24 mo (Mean) |
|---|---|
| Estriol Capsules Plus Copaxone Injections | 40.5 |
| Placebo Capsules Plus Copaxone Injections | 46.9 |
1 other study available for estriol and Demyelinating Diseases
| Article | Year |
|---|---|
Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease.
Topics: Animals; CA1 Region, Hippocampal; Cell Adhesion Molecules, Neuronal; Demyelinating Diseases; Disks L | 2012 |
Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease.
Topics: Animals; CA1 Region, Hippocampal; Cell Adhesion Molecules, Neuronal; Demyelinating Diseases; Disks L | 2012 |
Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease.
Topics: Animals; CA1 Region, Hippocampal; Cell Adhesion Molecules, Neuronal; Demyelinating Diseases; Disks L | 2012 |
Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease.
Topics: Animals; CA1 Region, Hippocampal; Cell Adhesion Molecules, Neuronal; Demyelinating Diseases; Disks L | 2012 |